Millions of people use cocaine every year. Doctors still have no reliable cocaine addiction treatment to offer them. A sweeping new review from the University of Bristol pooled data from 163 clinical trials and tested 89 different medicines. The verdict leaves little room for doubt. Not one drug shows convincing evidence that it works.

A Widespread Problem With No Licensed Drug

The UN World Drug Report 2025 counts around 25 million cocaine users in the past year. That figure represents 0.5% of the world’s population. About one in five of these users will go on to develop cocaine use disorder within two years.

Long term use raises the risk of death from any cause. It also damages the heart and harms memory, attention and impulse control. At a wider level, cocaine use fuels violence and crime. It also drives the spread of blood borne diseases such as HIV and hepatitis C.

Despite this toll, no country has licensed a medicine for cocaine addiction treatment. No standard care pathway exists anywhere in the world.

Researchers Pool 163 Trials to Test the Evidence

Researchers from the University of Bristol led the study. They worked alongside the National Institute for Health and Care Research. Together they pooled data from 163 clinical trials involving almost 15,000 participants worldwide.

The team tested 89 different medicines across eight broad categories. These ranged from antidepressants to anticonvulsants, and from opioid based drugs to experimental antagonists. The team published its findings in the journal Addiction. Their conclusion was blunt. Current evidence cannot support any drug based cocaine dependence treatment.

Measuring More Than Whether a Drug Works

The review looked well beyond a simple yes or no. Researchers examined 12 separate measures of effectiveness. They also assessed three measures of patient acceptability. Two more measures covered safety, including serious side effects and deaths. Any credible cocaine addiction treatment must clear all of these hurdles, not just one.

The quality of the evidence raised real concerns. Reviewers rated nearly half of the individual results, 48%, as high risk of bias. They judged just 16% as low risk. Most findings deserve a healthy dose of scepticism as a result.

Flickers of Promise That Do Not Hold Up

A handful of drug categories did show flickers of promise, at least on paper. Antidepressants and other serotonin based medicines raised the odds of staying abstinent during treatment. The increase reached roughly 74%, compared with placebo. Anticonvulsant medicines carried more than eight times the odds of abstinence at a single point, again compared with placebo.

These apparent benefits did not survive closer scrutiny. The same antidepressants barely moved the needle on how often or how much people actually used cocaine. Anticonvulsants that looked promising for one type of abstinence showed no such benefit for cocaine use itself. Researchers rated every one of these findings as very low certainty evidence. They believe the mismatches suggest chance findings rather than a genuine drug effect. Even so, none of this amounts to a proven cocaine addiction treatment.

No Clear Danger, But Too Little Data to Be Sure

On safety, no class of medicine stood out as more dangerous than placebo. However, the trials recorded remarkably few serious adverse events. Just four deaths occurred across all 163 studies. That leaves too little data for anyone to draw firm conclusions either way. Any future cocaine dependence treatment must still prove itself safe as well as effective.

The Search for a Cocaine Addiction Treatment Goes Back Decades

None of this will surprise anyone who has followed the long hunt for an effective cocaine addiction treatment. As far back as 2008, an expert US review already described the decades long search as disappointing. By that point, government funded testing had covered more than 60 marketed medicines.

Candidates that once seemed hopeful have never turned into anything doctors can reliably prescribe. Modafinil is a mild stimulant that doctors also prescribe for narcolepsy, and it showed early promise for helping people begin abstinence. Doctors know disulfiram by its brand name, Antabuse. It appeared in four published trials that suggested it reduced cocaine use. Researchers also named one experimental cocaine vaccine TA CD, which aimed to stop cocaine molecules crossing the blood brain barrier. All three generated encouraging early results. None became a lasting cocaine dependence treatment.

Many European clinicians still rely mostly on psychosocial support to reduce cocaine related harm, rather than on medication.

Gaps That Make the Evidence Harder to Trust

The patchy, inconsistent nature of the evidence base is itself part of the problem, the Bristol team says. Trials have used wildly different measures of success. Few reported whether participants also faced other substance use or mental health conditions. Most studies focused on helping people stop using cocaine in the first place, rather than on preventing relapse afterwards. Only a small number of studies looked specifically at relapse prevention. That leaves a real gap in understanding what helps people stay off cocaine for good.

Where This Leaves Prevention

Cocaine use disorder continues to affect millions of people worldwide. No medicine can yet deliver reliable cocaine addiction treatment. For now, stopping cocaine use before it takes hold looks a far surer bet. Hoping a future pill can undo the damage does not.

Source: dbrecoveryresources